-- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA) reduction with extended overall survival -- -- GRANITE has ...
First-in-human study in patients with solid tumors initially evaluating the safety, tolerability pharmacokinetics and target engagement of RGT-61159 WOBURN, Mass., Oct. 8, 2024 /PRNewswire/ -- Rgenta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback